Global biopharmaceutical firm Santen SA and Sydnexis have entered an exclusive licensing deal for a drug formulation that aims to treat progressive myopia. The agreement covers Europe, Middle East, and Africa (EMEA) region.
Visionary Ventures led a $45MM round into its 12th portfolio company, Sydnexis. Sydnexis is a clinical stage biopharmaceutical company with a proprietary formulation of low dose atropine for the treatment of progressive myopia, today announced the completion of a $45 million Series B financing led by Visionary Ventures, Blue Stem Capital, and SC Master Fund, with participation from existing investors RA Capital Management, Longitude Capital, and Medicxi. The financing will be used to fund Sydnexis’ lead candidate, SYD-101, through completion of the fully enrolled pivotal Phase 3 STAAR study for the treatment of progressive myopia in children.